See Dr. Dahl’s publications here

1. Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P; CNODES Investigators. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. N Engl J Med. 2016 Mar 24;374(12):1145-54.

2. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581.

3. Harris D, Barts A, Connors J, Dahl M, Elliott T, Kong J, Keane T, Thompson D, Stafford S, Ur E, Sirrs S. Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol. 2013 Dec;20(6):e532-8.

4. Cameron, C, Virani A Dean H, Evans M,Dolovich L, Dahl M Utilization and Expenditure on Blood Glucose Test Strips in Canada. Canadian Journal of Diabetes. 2010; 34 (1):34-40.

5. McIntosh B, Yu C, Lal A, Chelak K, Cameron C, Singh S, Dahl M  Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis.  Open Medicine 2010;4(2):e102.

6. Dahl M, Feldman J, Goldberg JM, Jaberi A Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism  2006; Vol 9 Issue: ¾, p111-134.